Who is on it, and how far along Every drug ChEMBL records acting on PDE3A, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Small molecule 6 Protein or peptide 1 Approved5 Anagrelide Anagrelide SponsorTakeda Pharmaceuticals USA ModalitySmall molecule ActionInhibitor Open trials4 Ensifentrine Ensifentrine SponsorMerck & Co. (MSD) ModalitySmall molecule ActionInhibitor Open trials3 Enoximone Enoximone SponsorGilead Sciences ModalitySmall molecule ActionInhibitor Open trials1 Theophylline anhydrous Theophylline anhydrous SponsorOrganon ModalityProtein or peptide ActionInhibitor Open trials1 Theophylline glycinate Theophylline glycinate SponsorCent Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials0 Phase 31 Levosimendan Levosimendan SponsorTenax Therapeutics ModalitySmall molecule ActionInhibitor Open trials9 Phase 21 K-134 K-134 SponsorKowa Research Institute, Inc. ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Phosphodiesterase 3 inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 17 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy Levosimendan Not applicable Recruiting Meshalkin Research Institute of Pathology of Circulation Nov 4, 2026 Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) Ensifentrine Phase 3 Recruiting Merck Sharp & Dohme LLC Oct 15, 2026 Artificial Voice Analysis and Telemonitoring for Heart Failure. A Feasibility Study Levosimendan Not applicable Recruiting Niguarda Hospital Jun 24, 2026 Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture Headache Theophylline anhydrous Not applicable Recruiting Tanta University Apr 7, 2026 Long-Term Open-Label Extension Study of Oral Levosimendan Levosimendan Phase 3 Enrolling by invitation Tenax Therapeutics, Inc. Feb 27, 2026 LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Levosimendan Phase 3 Active, not recruiting Tenax Therapeutics, Inc. Dec 17, 2025 Levosimendan in Acute Decompensated Heart Failure Levosimendan Phase 2 / Phase 3 Not yet recruiting Chittagong Medical College Dec 4, 2025 Shorter Weaning From Invasive Ventilation With Levosimendan Levosimendan Phase 4 Recruiting Radboud University Medical Center Aug 5, 2025 Pharmacokinetic Modelling of Levosimendan in Adults Levosimendan — Not yet recruiting University Hospital, Rouen May 29, 2025 A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis Ensifentrine Phase 2 Recruiting Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aug 19, 2024 A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Anagrelide Phase 3 Active, not recruiting Merck Sharp & Dohme LLC Oct 12, 2023 LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF Levosimendan Phase 3 Active, not recruiting Tenax Therapeutics, Inc. Aug 9, 2023 Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) Ensifentrine Phase 2 Active, not recruiting Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Mar 8, 2022 Unloading in Heart Failure Cardiogenic Shock Enoximone Not applicable Not yet recruiting Amsterdam UMC, location VUmc Oct 1, 2021 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis Anagrelide Phase 2 Active, not recruiting Karyopharm Therapeutics Inc Sep 24, 2020 Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance Anagrelide Phase 3 Active, not recruiting PharmaEssentia Feb 26, 2020 The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Anagrelide Phase 2 Active, not recruiting RWTH Aachen University Oct 16, 2015
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2094125 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets